philipp ivanyi

⏱️ Der ASCO GU 2026 steht vor der Tür! Es erwarten Sie aktuelle Kongress-Highlights sowie spannende Diskussionen mit führenden Expert:innen – direkt vom Kongress. Auf onkowissenTV sind Sie nah dran an den wichtigsten neuen Erkenntnissen aus der Uro-Onkologie. 👉 Jetzt kostenfrei anmelden und nichts verpassen unter: onkowissen.tv/beitraege/asco… #ASCOGU2026 #UroOnkologie #Onkologie #MedWissen #Healthcare #MedEd

There has been a lot of data on ctDNA in bladder cancer #GU26, but less on tumor DNA in the urine (utDNA). In this informed utDNA analysis from NIAGARA we show extensive utDNA positivity at baseline & clearance with neoadjuvant therapy. There is also a better correlation with utDNA and pCR than with ctDNA. This dual approach helps determine the origin of thr MRD (local vs systemic). False positive rates at CR need addressing. Clearance could be a marker of local therapy activity #GU26 @MichvdHeijden @MattGalsky

⏱️ ASCO GU 2026 is just around the corner! Stay tuned for exclusive congress highlights and expert discussions – bringing you the latest insights directly from the meeting. On high5oncologyTV, you’ll be close to the most important new developments in genitourinary oncology. 👉 Register now for free and don’t miss out! high5oncology.tv/meeting-covera… #ASCOGU2026 #GUOncology #Oncology #MedicalEducation #Healthcare #MedEd

Dear colleagues at #GU26, Our friends and collaborators at High5Oncology are on the ground in San Francisco capturing the key discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology. Their exclusive coverage will be going LIVE in the coming days — stay tuned and follow along here: buff.ly/WQZpPkz Tagging some of the amazing @high5md GU faculty @amerseburger @EfstathiouEleni @weoncologists @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini @OncoBellmunt @scserendipity1 @GoebellJ @PGrivasMDPhD @IvanyiPhilipp @y_loriot @tompowles1 @bjartell @scserendipity1 @EfstathiouEleni @grimm_mo @amerseburger @declangmurphy @nealshore @OncoAlert

Dear colleagues at #GU26 Our friends and collaborators at High5Oncology were on the ground in San Francisco capturing THE KEY discussions from ASCO GU and highlighting the innovations shaping the future of GU oncology and THEIR GU26 PAGE IS SOON LIVE!! FIND THEM HERE 👉 buff.ly/WQZpPkz Tagging some of the amazing @high5md GU faculty @amerseburger @EfstathiouEleni @weoncologists @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini @OncoBellmunt @scserendipity1 @GoebellJ @PGrivasMDPhD @IvanyiPhilipp @y_loriot @tompowles1 @bjartell @scserendipity1 @EfstathiouEleni @grimm_mo @amerseburger @declangmurphy @nealshore @OncoAlert

Top #GUcancer abstracts at #ESMO25 via #high5oncologyTV: 🔹 LBA6: Lu-PSMA-617 + ADT/ARPI (mHSPC) 🔹 LBA2: EV + pembro periop (MIBC) 🔹 LBA8: ctDNA-guided atezo (MIBC) 🔹 LBA87: Enza in biochem recurrent PCa 🔹 LBA93: Durva ± treme (adjuvant RCC) 📺 Full coverage soon on high5oncology.tv - stay tuned! #ProstateCancer #BladderCancer #KidneyCancer @OncoBellmunt @scserendipity1 @nachoduranm @EfstathiouEleni @GoebellJ @grimm_mo @PGrivasMDPhD @HHammersMD @IvanyiPhilipp @y_loriot @amerseburger @weoncologists @declangmurphy @tompowles1 @nealshore @montypal @OncoAlert

Great pleassure to give a lecture @Persue Meeting on #HeadandNeckCancer in Cairo! Previliged to discuss several topica with Great colleagues!

Philipp Ivanyi Highlights Need for Reconsideration in Cancer Treatment Landscape oncodaily.com/insight/philip… @IvanyiPhilipp #CancerTreatment #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

Comprehensive Overview done with highly respected colleagues! However, needs to be reconsidered due to rapidly changing landscape#CancerTreatmentReviews #cancer @szturtz @thorstenfuereder @paolobossi

@tompowles1 Congratulations Tom @tompowles1 and the team. These practice-changing data have brought ctDNA testing to the forefront of decision-making regarding adjuvant therapy in our patients with bladder cancer. #BladderCancer @NateraGenetics

✍️🇫🇷 SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER @SFjROfr sciencedirect.com/science/articl…

Congrats to slyer and #@ProfJacob, thx letting me join the project! Impotant insights towarts (un?)value of certification process?

Interesting insights! Congrats to#@wenji@#Jonathans Lab! Looking forward to next Common Step.

Prostata, Blase, Niere – die wichtigsten Studien des Jahres jetzt online verfügbar: onkowissen.tv/beitraege/asco… @jcasusce @GoebellJ @grimm_mo @ProfHadaschik @ProfKHerrmann @IvanyiPhilipp @amerseburger @martin_schostak @Tilki_De

Great Meeting! Nice to see/discuss with Friends&collegues#IKCS25. Lectures availableand worth to see: kidneycancer.swoogo.com/ikcseu25/84277…

@syt_40 No Doubt! CPS(+) nonccRCC R candidates 4 COI/CPI, none the less, once remission pressure is the Topic Consumer PD1/TKI, based on current data#sunniforcast#Iagn@RCC

@IvanyiPhilipp Great to see the SUNNIFORECAST trial's impact on nccRCC treatment! The results seem promising, do you think this could become the new standard of care based on the data?

Published! Previliged to be a Part of SUNNIFORCAST! World largest ranomized trial on #non-ccRCC #kidney cancer deiven by Academia #MHH

💥Neoadjuvant pembrolizumab has received the approval for PDL1 CPS≥1 head&neck SCC by FDA! 🛎️This will require quick CPS testings Not surprising seen this restricion for negative CPS, having only 16 patients in each arm of KEYNOTE689 without presenting their specific outcomes @OncoAlert @brunolarvol @OncBrothers

RCC updates from #ASCO25 are live on high5oncologyTV 🧬 Summarized in 100 seconds and thoroughly discussed by experts: high5oncology.tv/meeting-covera… @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini #KidneyCancer #RCC #RenalCellCarcinoma #ASCO2025 #ImmunoOncology #CancerResearch #CheckpointInhibitors #TargetedTherapy #high5oncologyTV #OncologyUpdates #ClearCellRCC

Missed ASCO? Get the key insights now – fast & free 👉 high5oncologyTV: high5oncology.tv/meeting-covera… @StephenVLiu @DrRiyazShah @GriesingerFrank @MartinReck2 @NReguart @HendriksLizza @nicogirardcurie @DMSLung @HosseinBorghaei @OncoBellmunt @bjartell @scserendipity1 @nachoduranm @EfstathiouEleni @GoebellJ @grimm_mo @PGrivasMDPhD @HHammersMD @IvanyiPhilipp @y_loriot @amerseburger @weoncologists @declangmurphy @tompowles1 @nealshore @montypal @E_de_Azambuja @evaciruelos @JavierCortesMD @curijoey @RebeccaDSing @ALEDIGNUS12 @DLueftner @volkmar_mueller @BarbaraPistill2 @hoperugo @stolaney1

Verpasst? Kein Problem! Die wichtigsten Erkenntnisse vom #ASCO25 gibt’s jetzt als Video on demand auf onkowissenTV ➡️ onkowissen.tv/beitraege/asco… @jcasusce @docchristoffer @GoebellJ @GriesingerFrank @grimm_mo @ProfHadaschik @HartkopfAndreas @ProfKHerrmann @IvanyiPhilipp @DavidKrugMD @DLueftner @amerseburger @ModestDominik @volkmar_mueller @juliaradosa @MartinReck2 @ReinacherAnke @martin_schostak @ProfMarcThill @Tilki_De @ArndtVogel